Genoma Lab40 revenue MXN4.02B, estimated MXN4.28B

Genoma Lab40 revenue MXN4.02B, estimated MXN4.28B

Genomma Lab Internacional Reports Revenue Decline in 2025, Reflects on Long-Term Performance

Genomma Lab Internacional, S.A.B. de C.V. (LABB.MX), a Mexican multinational corporation specializing in consumer goods and pharmaceutical products, reported trailing twelve-month revenue of $0.94 billion USD as of 2025, marking a 4.37% decline compared to $0.99 billion USD in 2024. This follows a period of growth in recent years, including a 12% increase in 2023 and an 11.18% rise in 2022.

The company's revenue trajectory since 2009 has been characterized by volatility, with notable peaks and troughs. For instance, revenue surged by 21.09% in 2021 ($0.76 billion USD) and 51.23% in 2010 ($0.50 billion USD), while contractions occurred during the 2020 pandemic (-4.78%) and the 2015-2016 period (-11.82% and -20.16%, respectively) according to revenue data. The 2025 decline continues a trend observed in 2014 (-2.95%) and 2018 (-8.16%), underscoring periodic challenges in sustaining consistent growth.

While the latest figures indicate a near-term slowdown, Genomma Lab Internacional's market capitalization remains tied to its shares outstanding, which are calculated using data from its most recent filings. The company's float—the number of publicly tradable shares—is derived by subtracting restricted stock from issued shares, a metric relevant to liquidity assessments.

Analysts may attribute the 2025 revenue contraction to macroeconomic factors, competitive pressures, or shifts in consumer demand, though the company has not publicly detailed specific causes. Investors are advised to monitor upcoming quarterly reports for insights into operational adjustments and long-term strategic direction.

For context, the company's historical revenue averages $0.84–$0.99 billion USD annually over the past five years, suggesting a resilient, albeit fluctuating, business model.